Water-vapor therapy (Rezūm): what the recovery and delayed benefit really mean

The size label changed—evidence still has layers

The current FDA-cleared labeling covers men 50 and older with prostate volumes from 30 through 150 cm³ and includes central-zone or median-lobe hyperplasia. This is broader than the original 30–80 cm³ pivotal population.

A broader label does not make outcomes identical at every size. Larger glands often require more injections, more catheter time, a longer inflammatory phase, and especially careful counseling about whether HoLEP, Aquablation, or simple prostatectomy would provide more predictable relief. Prospective large-gland data support feasibility, but the deepest randomized durability evidence remains in the original moderate-size population.

Median lobes and treatment planning

A median lobe can be treated, but only if it is recognized and deliberately targeted. A “Rezum provider” is not automatically a provider with equal experience in median-lobe, retention, or 100-plus-cc cases.

Imaging and cystoscopic anatomy should drive the injection map. Ask whether the center documents prostate volume, urethral length, middle-lobe configuration, baseline residual urine, and bladder function before treatment.

A realistic recovery trajectory

Procedure day is often brief. The more important planning window is the first one to two weeks. A catheter is common for several days, and some men need longer. After removal, urgency, frequency, burning, intermittent blood, pelvic pressure, and a variable stream are expected while inflammation settles.

Improvement is commonly gradual rather than dramatic. A reasonable follow-up plan separates early safety checks from the later efficacy decision. Declaring failure at ten days is usually premature; waiting months without checking retention, infection, or bladder emptying is also inappropriate.

Sexual function and retreatment

Randomized follow-up shows a low rate of new sustained erectile or ejaculatory dysfunction, making WVTT attractive when sexual preservation matters. Preservation is not absolute, and temporary painful ejaculation, reduced volume, or changes in sensation can occur.

Five-year pivotal follow-up supports durable average improvement with a relatively low surgical-retreatment rate. Real-world “failure” can also include resuming medication, incomplete treatment of anatomy, persistent bladder-driven symptoms, or a patient deciding that moderate relief is no longer enough.

Capability questions for the treating urologist

• How long do patients with my gland size typically keep a catheter in your practice?
• How many injections do you anticipate, including the middle lobe?
• What is your protocol for a failed voiding trial, urinary infection, or prolonged inflammation?
• When do you repeat symptom score, flow, and residual urine?
• At what point would you recommend a second WVTT treatment versus HoLEP, TURP, or Aquablation?